FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
RUBY Financial Statements
Year
2022
2021
2020
2019
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
127.25M
194.62M
166.45M
169.6M
Research and Development
96.41M
141.59M
116.11M
112.42M
Selling, General & Administrative Expenses
30.84M
53.03M
50.34M
57.18M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
30.84M
53.03M
50.34M
57.18M
Other Expenses
1.82M
-1.93M
-1.28M
6.14M
Operating Income
-178.45M
-194.62M
-166.45M
-169.6M
Total Other Income/Expenses Net
-1.22M
-1.93M
-1.28M
6.14M
Income Before Tax
-179.67M
-196.55M
-167.73M
-163.46M
Income Tax
51.2M
-7.72M
-5.69M
-3M
Net Income
-230.86M
-188.82M
-162.04M
-160.46M
Basic EPS
-2.56
-2.15
-2.01
-2.04
EPS Diluted
-2.56
-2.15
-2.01
-2.04
Basic Average Shares
90.31M
87.95M
80.62M
78.69M
Diluted Average Shares
90.31M
87.95M
80.62M
78.69M
EBITDA
-118.35M
-194.62M
-166.45M
-169.6M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-677.02M
-480.47M
-312.74M
-150.08M
Net Income
-230.86M
-188.82M
-162.04M
-160.46M
Stock Repurchases
0
0
0
-122k
Dividend Paid
0
0
0
0
Retained Earnings
-856.68M
-677.02M
-480.47M
-312.74M
Other Distributions
-179.67M
-196.55M
-167.73M
-162.78M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
2.83M
86.63M
94.4M
103.48M
Annual Depreciation
6.25M
7.72M
5.69M
3M
Capital Expenditure
-5.3M
-3.65M
-5.5M
-40.66M
Net PPE
1.88M
82.55M
94.2M
141.15M
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
